CERo Therapeutics Holdings, Inc. (CERO)

OTCMKTS · Delayed Price · Currency is USD
0.0410
+0.0010 (2.50%)
At close: Feb 23, 2026
Market Cap1.18M -68.8%
Revenue (ttm)n/a
Net Income-49.19M
EPS-98.71
Shares Out28.66M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume202,236
Average Volume621,353
Open0.0399
Previous Close0.0400
Day's Range0.0393 - 0.0410
52-Week Range0.0350 - 35.0000
Beta0.30
RSI32.28
Earnings DateMar 23, 2026

About CERO

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Employees 8
Stock Exchange OTCMKTS
Ticker Symbol CERO
Full Company Profile

Financial Performance

Financial Statements